Showing posts with the label Bausch Health

Bausch Health Initiates Second Phase 3 Study For NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction

IndustryPRwire -- Bausch Health Companies and Bausch + Lomb announced that the Company has initiated the second of two Phase 3 studies evaluating the investigational treatment NOV03 (perfluorohexylo…

Nicox’s Licensee Bausch + Lomb Launches VYZULTA in Argentina

Nicox SA announced that its exclusive global licensee Bausch + Lomb has launched VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Argentina.  Regulatory approval in Argentina was obtai…

Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease

Bausch Health Companies and its gastroenterology business, Salix Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to rifaximin for the treatm…

Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses

Bausch + Lomb today announced the introduction of the SimplifEYE™ intraocular lens (IOL) delivery system, which is available exclusively for the enVista® MX60PL and the enVista® toric MX60PT, the fi…

Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens

Bausch Health Companies along with BHVI announced today that an affiliate of Bausch Health has acquired an exclusive license for a myopia control contact lens design developed by BHVI. Bausch + Lomb …

Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12

Bausch Health Companies and Eyenovia announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an inv…
Subscribe Our Newsletter